A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

Imiquimod is an orally active interferon inducer with anti-tumour activity in experimental animals. In this study the tolerability, toxicity and biological effects of daily oral imiquimod administration were investigated in 21 patients with refractory cancer. Patients were treated with doses of 25 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Savage, P., Horton, V., Moore, J., Owens, M., Witt, P., Gore, M. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074776/
https://www.ncbi.nlm.nih.gov/pubmed/8912549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074776/
https://www.ncbi.nlm.nih.gov/pubmed/8912549

Ejemplares similares